HeartFlow/$HTFL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About HeartFlow
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.
- Ticker
- $HTFL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 843
- Headquarters
- San Francisco, United States
- Website
- www.heartflow.com
HeartFlow Metrics
BasicAdvanced
$5.3B
-
-$1.54
-
-
Price and volume
Market cap
$5.3B
52-week high
$60.56
52-week low
$20.13
Average daily volume
1.8M
Financial strength
Current ratio
5.08
Quick ratio
4.657
Long term debt to equity
0.073
Total debt to equity
0.097
Interest coverage (TTM)
-21.02%
Profitability
EBITDA (TTM)
-71.355
Gross margin (TTM)
80.08%
Net profit margin (TTM)
-55.82%
Operating margin (TTM)
-34.31%
Effective tax rate (TTM)
0.08%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
-18.05%
Return on equity (TTM)
-154.23%
Valuation
Price to revenue (TTM)
21.904
Price to book
18.76
Price to tangible book (TTM)
18.76
Price to free cash flow (TTM)
-78.493
Free cash flow yield (TTM)
-1.27%
Free cash flow per share (TTM)
-0.771
Growth
Revenue change (TTM)
42.77%
Earnings per share change (TTM)
-90.13%
What the Analysts think about HeartFlow
Analyst ratings (Buy, Hold, Sell) for HeartFlow stock.
Analyst projections of the future price of HeartFlow stock.
Bulls say / Bears say
Second-quarter revenue rose 48% year on year to $64.1 million, and HeartFlow raised its 2026 revenue outlook to $246–250 million, implying 40–42% growth. This points to strong commercial momentum. (HeartFlow)
Gross margin expanded to 83.3% from 75.6% a year earlier, while the non-GAAP operating loss narrowed. If volume growth and AI-driven efficiencies continue, the business could become more profitable as it scales. (HeartFlow)
An independent, government-funded trial found HeartFlow’s FFR CT pathway reduced unnecessary invasive angiography by 44% at one year, without a rise in adverse safety outcomes. Evidence of clinical value could support wider use. (GlobeNewswire)
HeartFlow remains loss-making: it reported a $15.7 million net loss in Q2 and says it expects further losses for the foreseeable future. Its $246.8 million in cash and investments must support the business while it pursues profitability. (SEC)
Revenue depends heavily on two products, and Plaque Analysis is still in the early stages of commercial adoption. Weaker uptake, reimbursement changes or stronger competitors could undermine growth and delay profitability. (SEC)
An August valuation analysis put HeartFlow at 17.3 times sales, well above the healthcare-services and peer averages it cited. Such a premium leaves the shares vulnerable if adoption or growth falls short of expectations. (Yahoo Finance)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.
HeartFlow Financial Performance
Revenues and expenses
HeartFlow Earnings Performance
Company profitability
Upcoming events
No upcoming events
HeartFlow News
AllArticlesVideos
Funds containing HeartFlow
Fund name | Fund size | $HTFL weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.15% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.15% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.05% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.05% |
iShares MSCI World Small Cap£WLDS | $9B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.